Cartalax 20 mg
A catalogue name; the candidate tripeptide AED requires sequence confirmation.
CAD $100.00 / vial
Vial amount
The specifics, clearly listed.
Product details
Product reference: MRD-0035 Listed amount per vial: 20 mg Sales unit: 1 vial
Read the research in context.
A catalogue name; the candidate tripeptide AED requires sequence confirmation.
- Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro — source
- Peptide normalizing metabolism in osseous and cartilage tissue, pharmaceutical composition based on thereof and method for its using — source
Candidate-molecule or reference-product background; not verification of this supplied product.
What this doesn’t establish: Cartalax trade-name-to-sequence match is provisional. AED must not be merged with AEDG (epitalon-related) or AEDR. Exact supplied identity/form, measured amount, lot-linked quality reports, purity, sterility/endotoxin, storage/stability and authorization are not established by these references.
Product documents
No verified report is available here for this item. Ask about documentation for Cartalax, product reference MRD-0035.
Before you decide.
Separate research about the compound from evidence about the supplied product.
Which vial amount is shown?
This listing shows 20 mg per vial.
Does the study verify this vial?
No. Research on a compound does not establish the identity, quality, safety or effectiveness of a product sold under that name.
What should I check in a report?
Check the sample identity, batch reference, issuer, date, test methods and results. A report applies to the identified sample and tests.
What information should I request?
Ask about the exact product identity, form, specification, handling requirements and relevant batch documents before deciding.